The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re bioMSAR Testing at Aquafuel Research Ltd

31 Jan 2022 07:00

RNS Number : 0661A
Quadrise Fuels International PLC
31 January 2022
 

31 January 2022

Quadrise Fuels International plc

("Quadrise" or the "Company")

 

Update re bioMSAR Testing at Aquafuel Research Ltd

 

Quadrise (AIM:QFI)the supplier of MSAR® and bioMSAR™ emulsion technology and fuels, is pleased to confirm the results of the latest bioMSAR™ testing at Aquafuel Research Ltd's ("Aquafuel") UK test facility.

The results relate to further engine optimisation testing of bioMSAR™, conducted on the Company's Cummins high-speed 4-stroke diesel engine generating set, to allow accurate performance monitoring, optimisation and measurements to be made. They follow the initial testing at Aquafuel, the results of which were published by the Company on 1 February 2021. 

During 2021 the engine was modified to allow injection timing to be advanced and performance to be monitored more accurately. These enhancements provided the ability to assess and optimise engine efficiency and emissions whilst using bioMSAR™ and other fuels.

Initial baseline runs under the latest testing were undertaken to ensure prior bioMSAR™ performance results were repeatable. These confirmed previously announced engine efficiency benefits of 3% and reductions of Nitrogen Oxide ("NOx") emissions of over 20% in comparison to diesel fuel.

The next phase of testing now completed has demonstrated that by advancing injection timing, engine efficiency can be increased by over 13%, thereby further reducing fuel consumption and carbon dioxide ("CO2") emissions.

Ordinarily, higher engine efficiencies result in increased combustion temperatures and NOx emissions. However, of particular note, the latest tests at Aquafuel have confirmed that it was possible with bioMSAR™ to reduce the inlet air temperature to the same level as diesel. This resulted in NOx levels being further reduced by over 30%, some 45% lower than diesel fuel.

These latest tests have therefore shown that much higher diesel engine efficiency can be achieved with bioMSAR™, without increasing NOx emissions. Further tests are being planned with Aquafuel during the year to focus on fully defining efficiency and emissions optimisation settings.

Jason Miles, CEO of Quadrise, said:

"We are pleased to obtain these outstanding results for bioMSAR™, providing further technical endorsement of the potential of the fuel. The higher engine efficiency and lower emissions evidenced by Aquafuel's testing are highly attractive features for all future clients of bioMSAR™, particularly those with ambitious decarbonisation targets. These results support our plans for larger-scale bioMSAR™ testing this year, and ultimately commercialisation."

 

For further information, please refer to the Company's website at www.quadrisefuels.com or contact:

 

Quadrise Fuels International Plc

 

Jason Miles, Chief Executive Officer

+44 (0)20 7031 7321

David Scott, Head of Finance

 

Nominated Adviser

 

Cenkos Securities plc

 

Ben Jeynes

+44 (0)20 7397 8900

Katy Birkin

 

 

Broker

Shore Capital Stockbrokers Limited

 

Toby Gibbs

+44 (0)20 7408 4090

Fiona Conroy

 

Public & Investor Relations

 

Vigo Consulting

Patrick D'Ancona

Charlie Neish

+44 (0)20 7390 0230

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBMMJTMTIJTIT
Date   Source Headline
2nd Feb 20217:00 amRNSUpdate re Morocco and Greenfield Energy Projects
1st Feb 20217:00 amRNSUpdate re bioMSAR Testing at Aquafuel Research Ltd
27th Jan 20217:00 amRNSIssue of Equity
21st Jan 20217:00 amRNSJoint Development Agreement - MSC Shipmanagement
6th Jan 20217:00 amRNSIssue of Equity
4th Jan 20217:00 amRNSChange of Registered Office
18th Dec 202011:46 amRNSUpdate re Greenfield MSAR Trial
18th Dec 20207:00 amRNSbioMSAR Testing Update & Collaboration Agreement
15th Dec 20207:00 amRNSLaunch of bioMSAR
3rd Dec 20207:00 amRNSPublication of Americas White Paper
27th Nov 202012:13 pmRNSResult of AGM
27th Nov 20207:00 amRNSAGM Statement
24th Nov 20208:00 amEQSQuadrise Fuels International (QFI): The clean solution to a global problem
2nd Nov 20205:23 pmRNSPosting of Annual Report and Notice of AGM
26th Oct 20207:00 amRNSMorocco Update
5th Oct 20207:00 amRNSFinal Results, Investor Presentation & AGM Notice
7th Sep 20205:56 pmRNSIssue of Equity
7th Sep 20207:00 amRNSNotice of Results, Update and Investor Event
24th Aug 20207:00 amRNSIssue of Share Options
20th Aug 20207:00 amRNSIssue of Equity
18th Aug 20207:22 amRNSGreenfield MSAR Commercial Trial Agreement
17th Aug 20207:00 amRNSPublication of White Paper
17th Jul 20203:59 pmRNSInvestor Presentation
30th Jun 20209:18 amRNSHolding(s) in Company
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:37 pmRNSPrice Monitoring Extension
23rd Jun 20207:00 amRNSIssue of Equity
18th Jun 20207:00 amRNSStatement re MSAR Licensing and Upstream Trial
17th Jun 20201:47 pmRNSStatement re MSAR Licensing
2nd Jun 20207:00 amRNSInvestor Presentation
1st May 20207:00 amRNSFurther Statement re Covid-19 and Update
16th Apr 20202:21 pmRNSIssue of Equity
15th Apr 20207:00 amRNSDirectorate Change
30th Mar 20204:13 pmRNSNew Website
30th Mar 202011:02 amRNSHalf-year Report - Replacement
30th Mar 20207:00 amRNSHalf-year Report
24th Mar 202010:13 amRNSIssue of Equity
16th Mar 20207:00 amRNSStatement re Covid-19 and Morocco Pilot Trial
5th Mar 20209:10 amRNSUpdate on Morocco Pilot Trial
17th Feb 20207:00 amRNSNotice of Interim Results and Business Update
30th Jan 20207:00 amRNSAppointment of New Auditors
15th Jan 20207:00 amRNSDirectorate Changes
16th Dec 20198:38 amRNSDirectorate Change
29th Nov 20194:42 pmRNSResult of AGM
29th Nov 20197:05 amRNSIssue of Warrants
29th Nov 20197:00 amRNSAGM Update
29th Nov 20197:00 amRNSMaterial Transfer & Cooperation Agreement
6th Nov 20195:03 pmRNSPosting of Annual Report and Notice of AGM
10th Oct 20195:42 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSNew three-year Exclusive Agreement with Nouryon

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.